325 related articles for article (PubMed ID: 34470047)
1. DKK1 activates noncanonical NF-κB signaling via IL-6-induced CKAP4 receptor in multiple myeloma.
Li X; Wang J; Zhu S; Zheng J; Xie Y; Jiang H; Guo J; Wang Y; Peng Z; Wang M; Wang J; Wang S; Zhong Y; Liu Z
Blood Adv; 2021 Sep; 5(18):3656-3667. PubMed ID: 34470047
[TBL] [Abstract][Full Text] [Related]
2. DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination.
Zhang Q; Gong W; Wu H; Wang J; Jin Q; Lin C; Xu S; Bao W; Wang Y; Wu J; Feng S; Zhao C; Chen B; Liu Z
Carcinogenesis; 2021 Oct; 42(10):1223-1231. PubMed ID: 34546340
[TBL] [Abstract][Full Text] [Related]
3. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
4. CKAP4 is a Dickkopf1 receptor and is involved in tumor progression.
Kimura H; Fumoto K; Shojima K; Nojima S; Osugi Y; Tomihara H; Eguchi H; Shintani Y; Endo H; Inoue M; Doki Y; Okumura M; Morii E; Kikuchi A
J Clin Invest; 2016 Jul; 126(7):2689-705. PubMed ID: 27322059
[TBL] [Abstract][Full Text] [Related]
5. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Fabre C; Mimura N; Bobb K; Kong SY; Gorgun G; Cirstea D; Hu Y; Minami J; Ohguchi H; Zhang J; Meshulam J; Carrasco RD; Tai YT; Richardson PG; Hideshima T; Anderson KC
Clin Cancer Res; 2012 Sep; 18(17):4669-81. PubMed ID: 22806876
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
[TBL] [Abstract][Full Text] [Related]
8. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
9. The Dickkopf1-cytoskeleton-associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy.
Kikuchi A; Fumoto K; Kimura H
Br J Pharmacol; 2017 Dec; 174(24):4651-4665. PubMed ID: 28514532
[TBL] [Abstract][Full Text] [Related]
10. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
11. MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.
Liu Y; Cheng P; Zhao W; Zhu L; Sui J; Dai Y; Lai Y
Leuk Res; 2022 Mar; 114():106785. PubMed ID: 35074616
[TBL] [Abstract][Full Text] [Related]
12. Activation of the Dickkopf1-CKAP4 pathway is associated with poor prognosis of esophageal cancer and anti-CKAP4 antibody may be a new therapeutic drug.
Shinno N; Kimura H; Sada R; Takiguchi S; Mori M; Fumoto K; Doki Y; Kikuchi A
Oncogene; 2018 Jun; 37(26):3471-3484. PubMed ID: 29563607
[TBL] [Abstract][Full Text] [Related]
13. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
15. Dynamic palmitoylation controls the microdomain localization of the DKK1 receptors CKAP4 and LRP6.
Sada R; Kimura H; Fukata Y; Fukata M; Yamamoto H; Kikuchi A
Sci Signal; 2019 Nov; 12(608):. PubMed ID: 31744930
[TBL] [Abstract][Full Text] [Related]
16. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
17. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
[TBL] [Abstract][Full Text] [Related]
18. DKK1-CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness.
Iguchi K; Sada R; Matsumoto S; Kimura H; Zen Y; Akita M; Gon H; Fukumoto T; Kikuchi A
Cancer Sci; 2023 May; 114(5):2063-2077. PubMed ID: 36718957
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
Murray MY; Zaitseva L; Auger MJ; Craig JI; MacEwan DJ; Rushworth SA; Bowles KM
Cell Cycle; 2015; 14(14):2367-75. PubMed ID: 25565020
[TBL] [Abstract][Full Text] [Related]
20. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
